Compare FLR & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLR | BLCO |
|---|---|---|
| Founded | 1912 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | FLR | BLCO |
|---|---|---|
| Price | $45.11 | $17.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 14 |
| Target Price | ★ $49.57 | $17.31 |
| AVG Volume (30 Days) | ★ 2.7M | 413.8K |
| Earning Date | 11-07-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1235.20 | N/A |
| EPS | ★ 20.04 | N/A |
| Revenue | ★ $15,587,000,000.00 | $4,976,000,000.00 |
| Revenue This Year | N/A | $8.08 |
| Revenue Next Year | $5.34 | $5.77 |
| P/E Ratio | $2.24 | ★ N/A |
| Revenue Growth | N/A | ★ 6.23 |
| 52 Week Low | $29.20 | $10.45 |
| 52 Week High | $57.50 | $20.71 |
| Indicator | FLR | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 66.31 |
| Support Level | $42.39 | $16.39 |
| Resistance Level | $46.00 | $17.35 |
| Average True Range (ATR) | 1.49 | 0.48 |
| MACD | 0.35 | 0.08 |
| Stochastic Oscillator | 85.85 | 88.63 |
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.